CAR T - Cell Therapy

After the approval of the CD19 CAR-T many tumor molecules are being targeted by CAR discovery.
The most of developments are allogenic CAR-T which is easier to manufacture in large quantities.
The convenience and advantage is to use the perfect starting material from the vendor.
The TCR ( T cell receptor ) on T cells only recognizes foreign antigens that are displayed in the context of self MHC.

Lymphocytes T Cells are separated out in a process known as leukapheresis from the blood's patient. The rest of the blood is returned to the body.
T Cells are coated with antibody coated beads and T Cells are reprogrammed introducing a genetic sequence through a Lenteviral Vector. T cells produce surface receptors proteins called CARs( chimeric antigen receptor).
The CAR T cells can recognize and attach to specific marker proteins on the cancer cell surface and signaling its attacking and destruction.
Millions of CAR T cells are growing and expanded in the lab to produce millions of identical copies.
Infuse CAR T cell into patient and monitor the patient.
Our state of the art technology can infuse the CAR T Cells directly to the patient or enable transdermal controlled absorption through the skin into the lymphatic and systemic capillaries located at dermis skin layer just beneath epidermis.

T Cells as a part of adaptive immunity express surface receptors to respond to diverse types of antigens or even to unwanted tumor cells. CAR T Cell Therapy involves the reprograming of a Patient T Cell to target and attack tumor cells like Lymphoma and B cell malignancies which express the human B-Cell tumor antigen CD19.

CAR T Cell is a biosynthetic immunology and is constructed by joining together an antigen-targeting domain, an transmembrane domain and activation signaling domains from various genetic origins like signaling domains derived from human immune activating receptors ( CD28 OR 4-1BB ) to confer antitumor function to T Cells.

The company is assessing oncolytic antigens for Multiple Myeloma, Acute Myeloid Leukemia and Melanoma.